Insulin metformin composition
The insulin-metformin composition with specific additives and a coating addresses the challenge of combining insulin and metformin, achieving enhanced therapeutic efficacy by synergistically lowering blood glucose levels.
Patent Information
- Application Number
- CN202310650250.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
Existing insulin and metformin cannot be effectively combined for enhanced therapeutic effect in treating diabetes.
An insulin-metformin composition comprising therapeutically effective amounts of insulin or its pharmaceutically acceptable salts, metformin or its salts, N-(8-(2-hydroxybenzoyl)amino)caprylate, and polyoxyethylene sorbitan fatty acid ester, preferably with a specific weight ratio, optionally with an enteric coating, to facilitate combined use and improved therapeutic outcomes.
The composition achieves synergistic blood glucose-lowering effects, demonstrating significant reductions in blood sugar levels when administered orally, particularly when combined with an enteric coating.
Smart Images

Figure BDA0004264929860000021 
Figure BDA0004264929860000031 
Figure BDA0004264929860000032
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of drug combination, and in particular, relates to an insulin-metformin combination. Background Art
[0002] Diabetes is a chronic metabolic disease that poses a serious threat to global health. The ninth edition of the IDF report shows that there are currently 463 million adults suffering from diabetes.
[0003] Biguanide compounds are important drugs for the treatment of diabetes. Common biguanide compounds include metformin and phenformin. Their mechanism of action is to reduce the production of liver glycogen, inhibit the absorption of glucose in the intestine, and increase the peripheral absorption and utilization of glucose, thereby improving insulin sensitivity by increasing peripheral sugar intake and utilization.
[0004] Metformin is the first-line drug for controlling hyperglycemia in patients with T2DM and the basic drug in drug combination. It is recommended by diabetes treatment guidelines in many countries around the world. The 2020 version of the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes points out that metformin is currently the most commonly used hypoglycemic drug, with a variety of potential benefits beyond hypoglycemic effects (such as the treatment of cardiovascular disease, cardiovascular complications of diabetes, etc.), and does not increase the risk of hypoglycemia. If there are no contraindications, metformin should always be retained in the treatment plan for diabetes.
[0005] Insulin is the main drug for the treatment of type 1 diabetes. Insulin is also needed to control blood sugar in the late stage of type 2 diabetes.
[0006] Therefore, how to combine insulin and metformin to improve the therapeutic effect has always been a problem that needs to be solved in the field. Summary of the invention
[0007] 1. Problems to be solved
[0008] In view of the problem that existing insulin and metformin cannot be used in combination, the present invention provides an insulin-metformin composition, which comprises a therapeutically effective amount of insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and polyoxyethylene sorbitan fatty acid ester. The composition can realize the combined use of insulin and metformin, and effectively improve the therapeutic effect.
[0009] 2. Technical solution
[0010] To solve the above problems, the present invention adopts the following technical solutions.
[0011] The present invention provides an insulin-metformin composition, which comprises a therapeutically effective amount of insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and polyoxyethylene sorbitan fatty acid ester.
[0012] In one aspect, the present invention provides a medicine, which comprises the composition.
[0013] In one aspect, the present invention provides use of the composition and the drug in preparing a drug for treating or preventing hyperglycemia.
[0014] The invention discloses an insulin-metformin composition, which comprises a therapeutically effective amount of insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and polyoxyethylene sorbitan fatty acid ester.
[0015] Preferably, the insulin comprises porcine insulin, human insulin or bovine insulin.
[0016] Preferably, the insulin comprises recombinant human insulin.
[0017] Preferably, the polyoxyethylene sorbitan fatty acid ester comprises Tween 80.
[0018] Preferably, the weight ratio of insulin or its pharmaceutically acceptable salt, metformin or its pharmaceutically acceptable salt, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80 in the composition is
[0019]
[0020] or
[0021] or
[0022] or
[0023] or
[0024] or
[0025]
[0026] Preferably, the composition comprises insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80.
[0027]
[0028] or
[0029]
[0030] or
[0031]
[0032] Preferably, the composition comprises insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80.
[0033]
[0034]
[0035] or
[0036]
[0037] or
[0038]
[0039] Preferably, the pharmaceutically acceptable salt of insulin in the composition includes any one or a combination of hydrochloride, acetate, decanoate, benzenesulfonate or caprylate. Preferably, the pharmaceutically acceptable salt of metformin in the composition includes an inorganic acid salt or an organic acid salt. Preferably, the organic acid salt includes a saturated fatty acid salt or an unsaturated fatty acid salt. Preferably, the pharmaceutically acceptable salt includes acetate, hydrochloride, hydroiodide, phosphate, nitrate, sulfate, citrate, lactate, succinate, maleate, malate, isethionate, fumarate, sulfonate, sulfate, methanesulfonate, ethanesulfonate, naphthylsulfonate, valerate, propionate, butyrate, eicosate, iodide, succinate, succinate, hydroxyethylsulfonate, fumarate, sulfonate, sulfate, methanesulfonate, ethanesulfonate, naphthylsulfonate, valerate, propionate, butyrate, eicosate, iodide, succinate, hydroxyethylsulfonate, fumarate, sulfonate, succinate ... methanesulfonate, ethanesulfonate, naphthylsulfonate, valerate, propionate, butyrate, eicosate, iodide, succinate, hydroxyethylsulfonate, fumarate Any one or combination of carbon pentanoate, docosahexaenoate, docosapentaenoate, cholate, ursodeoxycholate or malonate. Preferably, the N-(8-(2-hydroxybenzoyl)amino)octanoate in the composition includes N-(8-(2-hydroxybenzoyl)amino)octanoate, which is any one or combination of sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, potassium N-(8-(2-hydroxybenzoyl)amino)octanoate, magnesium N-(8-(2-hydroxybenzoyl)amino)octanoate, calcium N-(8-(2-hydroxybenzoyl)amino)octanoate or ammonium N-(8-(2-hydroxybenzoyl)amino)octanoate.
[0040] A medicine, comprising any one of the above-mentioned compositions, preferably, the medicine comprises a coating, preferably, the coating comprises an enteric coating or a gelatin coating.
[0041] Preferably, the coating material may be Eudragit L30D, Eudragit L100, Eudragit S100, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate or shellac.
[0042] Preferably, the coating material may include Eudragit L30D, talcum powder, and polyethylene glycol, and the coating material is dissolved in dichloromethane and isopropanol to obtain a coating solution, and the coating solution is sprayed onto the surface of the capsule to obtain an enteric-coated capsule, wherein Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), and dichloromethane / isopropanol = 9:1 (volume ratio).
[0043] Preferably, the drug further comprises a pharmaceutically acceptable excipient. Preferably, the pharmaceutically acceptable excipient comprises a plasticizer, a preservative, a colorant, a lubricant, a flavoring agent, an excipient, a diluent, a fragrance, a solubilizer or a disintegrant.
[0044] Preferably, the drug is in oral or injectable form.
[0045] Use of any of the above compositions and any of the above drugs in the preparation of drugs for treating or preventing hyperglycemia, preferably, use of any of the above drugs in the preparation of drugs for treating or preventing type 2 diabetes, type 1 diabetes or obesity.
[0046] 3. Beneficial effects
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] (1) The composition of the present invention can achieve the combined use of insulin and metformin, effectively providing a therapeutic effect. DETAILED DESCRIPTION
[0049] The present invention is described in detail below.
[0050] Example 1
[0051]
[0052]
[0053] Preparation method
[0054] 5 mg recombinant human insulin, 250 mg metformin hydrochloride, 47.5 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 25 mg Tween 80 were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate is 0.5 ml / min, the coating temperature is 30°C to 35°C, and the coating weight gain is 10%.
[0055] Example 2
[0056] Recombinant human insulin 5mg Metformin hydrochloride 125mg Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate 80mg Twain 80 25mg
[0057] Preparation method
[0058] 5 mg recombinant human insulin, 125 mg metformin hydrochloride, 80 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 25 mg Tween 80 were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate was 0.5 ml / min, the coating temperature was 30°C to 35°C, and the coating weight gain was 10%.
[0059] Example 3
[0060] Recombinant human insulin 10mg Metformin hydrochloride 125mg Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate 270mg Twain 80 90mg
[0061] Preparation method
[0062] 10 mg recombinant human insulin, 125 mg metformin hydrochloride, 270 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 90 mg Tween 80 were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate is 0.5 ml / min, the coating temperature is 30°C to 35°C, and the coating weight gain is 10%.
[0063] Example 4
[0064] Animal experiments
[0065] Experimental Methods:
[0066] Establishment of diabetic mouse model:
[0067] The rats were fasted for 6 hours, and each rat was intraperitoneally injected with streptozotocin at a dose of 40 mg / kg, once a day. At the same time, they were fed with a high-fat diet, and fasting blood glucose was measured with a Roche blood glucose meter. The fasting blood glucose value was greater than 11.1 mmol / L, which was considered a successful model. Fifty rats were successfully modeled. The model mice were randomly divided into 5 groups, group A, group B, group C, group D, and group E (model group). There were 10 rats in each group. Another 10 rats without modeling were taken as the normal group.
[0068] Dosage:
[0069] Group A was intragastrically administered with the drug prepared in Example 1 at 50 mg / kg based on rat body weight for 8 consecutive weeks with normal drinking water and high-fat diet;
[0070] Group B was intragastrically administered the drug prepared in Example 2 at 50 mg / kg based on rat body weight for 8 consecutive weeks with normal drinking water and high-fat diet;
[0071] Group C was intragastrically administered with the drug prepared in Example 3 at 50 mg / kg based on rat body weight for 8 consecutive weeks with normal drinking water and high-fat diet;
[0072] Group D was gavaged with commercially available metformin tablets by catheter, 50 mg / kg based on rat body weight, for 8 consecutive weeks, with normal drinking water and high-fat diet;
[0073] The E group (model group) was intragastrically administered with 0.9% saline daily for 8 consecutive weeks, with normal drinking water and high-fat diet.
[0074] The normal group was gavaged with 0.9% saline daily for 8 consecutive weeks, and was fed with normal drinking water and feed.
[0075] Note: 50mg / kg refers to the dosage of metformin hydrochloride 50mg / Kg. The standard average weight of rats is about 200g. For example, in group A, the dosage of metformin hydrochloride is 50mg / Kg, then 10mg of metformin hydrochloride is used, and recombinant human insulin, sodium N-(8-(2-hydroxybenzoyl)amino)octanoate and Tween 80 are converted according to the corresponding proportions, such as the dosage of recombinant human insulin is 0.2mg, the dosage of sodium N-(8-(2-hydroxybenzoyl)amino)octanoate is 1.9mg, and the dosage of Tween 80 is 1.0mg. The calculations for groups B and C are similar.
[0076] Blood Glucose Monitoring:
[0077] The blood glucose levels of the animals in each group were measured at 0, 2, 4, 6 and 8 weeks after administration. Blood glucose was measured using a blood glucose meter.
[0078] in conclusion:
[0079] At week 0 (before administration), the average blood glucose values of groups A, B, C, D, and E were compared with those of the normal group, P < 0.05, indicating that the model was successfully established.
[0080] In the 8th week, the average blood glucose values of group A, group B, group C, and group D were compared with those of group E, P < 0.05, indicating that group A, group B, group C, and group D had a significant blood glucose-lowering effect.
[0081] At week 8, the average blood sugar levels of groups A, B, and C were compared with those of group D, P < 0.05, indicating that oral administration of recombinant human insulin and metformin can synergistically reduce blood sugar levels, with a significant reduction in blood sugar levels. Group C had the best blood sugar-lowering effect.
Claims
1. An insulin-metformin composition, comprising a therapeutically effective amount of insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and polyoxyethylene sorbitan fatty acid ester.
2. The composition according to claim 1, wherein the insulin comprises porcine insulin, human insulin or bovine insulin, preferably, the insulin comprises recombinant human insulin, preferably, the polyoxyethylene sorbitan fatty acid ester comprises Tween 80.
3. The composition according to claim 2, wherein the weight ratio of insulin or its pharmaceutically acceptable salt, metformin or its pharmaceutically acceptable salt, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80 is or or or or or 4. The composition according to claim 3, wherein the composition comprises insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80. or or 5. The composition according to claim 4, wherein the composition comprises insulin or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and Tween 80. or or 6. The composition according to any one of claims 1 to 5, wherein the pharmaceutically acceptable salt of insulin in the composition comprises any one or a combination of hydrochloride, acetate, decanoate, benzenesulfonate or caprylate, preferably, the pharmaceutically acceptable salt of metformin in the composition comprises an inorganic acid salt or an organic acid salt, preferably, the organic acid salt comprises a saturated fatty acid salt or an unsaturated fatty acid salt, preferably, the pharmaceutically acceptable salt comprises acetate, hydrochloride, hydroiodide, phosphate, nitrate, sulfate, citrate, lactate, succinate, maleate, malate, isethionate, fumarate, sulfonate, sulfate, methanesulfonate, ethanesulfonate, naphthylsulfonate, valerate, acetonate, acetonate, pyruv ... Any one or combination of esters, butyrates, eicosapentaenoic acid salts, docosahexaenoic acid salts, docosapentaenoic acid salts, cholates, ursodeoxycholates or malonates. Preferably, the N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt in the composition includes N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt, which is any one or combination of N-(8-(2-hydroxybenzoyl)amino)caprylic acid sodium, N-(8-(2-hydroxybenzoyl)amino)caprylic acid potassium, N-(8-(2-hydroxybenzoyl)amino)caprylic acid magnesium, N-(8-(2-hydroxybenzoyl)amino)caprylic acid calcium or N-(8-(2-hydroxybenzoyl)amino)caprylic acid ammonium.
7. A medicine, comprising the composition according to any one of claims 1 to 6, preferably, the medicine comprises a coating, preferably, the coating comprises an enteric coating or a gelatin coating.
8. The drug according to claim 7, further comprising a pharmaceutically acceptable excipient, preferably, the pharmaceutically acceptable excipient comprises a plasticizer, a preservative, a colorant, a lubricant, a flavoring agent, an excipient, a diluent, a fragrance, a solubilizer or a disintegrant.
9. The drug according to claim 7 or 8, which is in oral or injection form.
10. Use of the composition according to any one of claims 1 to 6 and the drug according to any one of claims 7 to 9 in the preparation of a drug for treating or preventing hyperglycemia, preferably, in the preparation of a drug for treating or preventing type 2 diabetes, type 1 diabetes or obesity.
